Last reviewed · How we verify
Naproxen-esomeprazole
Naproxen-esomeprazole is a NSAID with proton pump inhibitor combination Small molecule drug developed by University of Sao Paulo. It is currently FDA-approved for Osteoarthritis, rheumatoid arthritis, and other chronic pain conditions with reduced risk of NSAID-induced gastrointestinal ulcers. Also known as: CYP2C9, CYP2C19.
Naproxen-esomeprazole combines a nonsteroidal anti-inflammatory drug (NSAID) with a proton pump inhibitor to reduce inflammation and pain while protecting the stomach from NSAID-induced ulcers.
Naproxen-esomeprazole combines a nonsteroidal anti-inflammatory drug (NSAID) with a proton pump inhibitor to reduce inflammation and pain while protecting the stomach from NSAID-induced ulcers. Used for Osteoarthritis, rheumatoid arthritis, and other chronic pain conditions with reduced risk of NSAID-induced gastrointestinal ulcers.
At a glance
| Generic name | Naproxen-esomeprazole |
|---|---|
| Also known as | CYP2C9, CYP2C19 |
| Sponsor | University of Sao Paulo |
| Drug class | NSAID with proton pump inhibitor combination |
| Target | COX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Naproxen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Esomeprazole suppresses gastric acid secretion by inhibiting the H+/K+-ATPase pump in gastric parietal cells, protecting the gastrointestinal mucosa from NSAID-related damage and ulceration.
Approved indications
- Osteoarthritis, rheumatoid arthritis, and other chronic pain conditions with reduced risk of NSAID-induced gastrointestinal ulcers
Common side effects
- Dyspepsia
- Headache
- Diarrhea
- Abdominal pain
- Nausea
Key clinical trials
- Non Steroidal Anti-inflammatory Drugs in the Prevention of Bone Pain Flares After Palliative Radiotherapy (PHASE2)
- A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA) (PHASE4)
- Pharmacogenetic and Pharmacokinetics of Naproxen and Associated Naproxen-esomeprazole (PHASE4)
- Evaluation of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients (PHASE3)
- Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients (PHASE3)
- Comparison of the Clinical Efficacy of Naproxen, Associated or Not With Esomeprazol, in Lower Third Molar Removal (PHASE4)
- Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty? (PHASE2)
- Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naproxen-esomeprazole CI brief — competitive landscape report
- Naproxen-esomeprazole updates RSS · CI watch RSS
- University of Sao Paulo portfolio CI
Frequently asked questions about Naproxen-esomeprazole
What is Naproxen-esomeprazole?
How does Naproxen-esomeprazole work?
What is Naproxen-esomeprazole used for?
Who makes Naproxen-esomeprazole?
Is Naproxen-esomeprazole also known as anything else?
What drug class is Naproxen-esomeprazole in?
What development phase is Naproxen-esomeprazole in?
What are the side effects of Naproxen-esomeprazole?
What does Naproxen-esomeprazole target?
Related
- Drug class: All NSAID with proton pump inhibitor combination drugs
- Target: All drugs targeting COX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole)
- Manufacturer: University of Sao Paulo — full pipeline
- Therapeutic area: All drugs in Rheumatology / Gastroenterology
- Indication: Drugs for Osteoarthritis, rheumatoid arthritis, and other chronic pain conditions with reduced risk of NSAID-induced gastrointestinal ulcers
- Also known as: CYP2C9, CYP2C19
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing